Clinical trials
Breast Cancer Recurrent clinical trials
Below are recruiting breast cancer recurrent clinical trials, each written for real people, not researchers. We’re tracking 632 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07197580RecruitingPhase 3
Study of a targeted radiation therapy for advanced kidney cancer
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
Sydney, New South WalesAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT05746897RecruitingPhase 1
First-in-human test of an anti-PVRIG drug for advanced cancers
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
Dallas, TexasAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT06382818Recruiting
Personalized breast radiation based on risk and side effects
This trial tests whether radiation therapy can be personalized based on your risk of the cancer coming back and your risk of side effects from radiation. Depending on those factors, you may receive a tailored radiation plan that could be more or less intense.
MontpellierAges 18 years+ - NCT06953882RecruitingPhase 2
Skipping chemo after surgery for ER+ HER2- breast cancer
This study tests whether some people with a certain type of breast cancer (ER-positive, HER2-negative) can safely skip chemotherapy. After surgery, they receive a targeted pill (ribociclib) plus hormone therapy instead. The goal is to see if this approach works just as well with fewer side effects.
New Haven, ConnecticutAges 18 years+ - NCT06837792RecruitingPhase 2
T-DXd vs hormone therapy for HER2-low advanced breast cancer
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
SeoulAges 19 years+ - NCT07721753Recruiting
Online exercise and therapy for breast cancer mood
This study tests an online program that combines fun video-game exercises with talk therapy to help breast cancer patients who feel depressed or anxious. It takes place in Malaysia and is for Chinese-speaking adults.
Xinxiang, HenanAges 18 years+ - NCT04874064Recruiting
AI blood tests for triple-negative breast cancer after treatment
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
London, OntarioAges 18 years+ - NCT06642948Recruiting
AI system for exercise rehab in breast cancer survivors
This study tests a new AI-based skeleton recognition system to guide rehabilitation exercises for breast cancer survivors. It may help reduce pain and improve mobility for those taking aromatase inhibitors.
ShanghaiAges Any age - NCT06793332RecruitingPhase 2
Ivonescimab and Trodelvy for breast cancer with brain metastases
This trial tests two drugs (Ivonescimab and a Trop2 ADC) for people with triple-negative breast cancer that has spread to the brain. It aims to see if this combination can shrink brain tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07253987Recruiting
Cancer Survivors Program for Breast or Prostate Cancer
This study offers a program to help people who have completed their main treatment for early-stage breast or prostate cancer. It focuses on follow-up and support during survivorship, and you are still eligible if you are on certain maintenance therapies like hormone therapy.
BrnoAges 18 years+ - NCT05403554RecruitingPhase 1
Testing a new mesothelin-targeting drug for certain solid cancers
This Phase 1 study tests NI-1801, a drug designed to attach to a target on cancer cells (mesothelin). It may be given alone or with pembrolizumab to help shrink tumors in advanced cancers that have enough mesothelin on their cells.
ParisAges 18 years+ - NCT06082180RecruitingPhase 3
Preventive neck lymph node removal in low-risk thyroid cancer
This trial is for people with low-risk papillary thyroid cancer. It compares two surgical approaches: one that removes just the thyroid gland, and another that also removes some lymph nodes in the center of the neck as a preventive measure. The goal is to see if removing these lymph nodes helps prevent the cancer from coming back.
Beijing, Beijing MunicipalityAges 18–70 - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT05861830RecruitingPhase 3
Dalpiciclib plus hormone therapy after CDK4/6 treatment
This trial tests dalpiciclib together with hormone (endocrine) therapy in people with HR-positive, HER2-negative advanced breast cancer whose cancer has already responded poorly to a prior CDK4/6 inhibitor. It aims to see if this combination can better control the cancer after that earlier treatment has failed.
Beijing, Beijing MunicipalityAges 18–80 - NCT04802759RecruitingPhase 1/Phase 2
Testing drug combinations for recurrent or advanced ER-positive breast cancer
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
Duarte, CaliforniaAges 18 years+ - NCT04888975Recruiting
Device study for one-arm swelling after lymph surgery
This study tests a medical device (Dayspring Technology) to reduce swelling in the arm caused by breast cancer treatment and lymph surgery. You may be eligible if you have one-sided arm swelling after lymphatic surgery and meet safety checks for the device.
Palo Alto, CaliforniaAges 18 years+ - NCT04965064RecruitingPhase 2
Neratinib plus capecitabine for HER2-negative breast cancer brain mets
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
Rochester, New YorkAges 18 years+ - NCT07128030Recruiting
Moderate exercise for pain in breast cancer survivors
This study tests whether moderate exercise (like brisk walking) can help reduce pain and sensitivity in breast cancer survivors. It's designed for women who have finished their main treatments and still have discomfort in their arm or shoulder on the side where they had surgery.
MadridAges Any age - NCT07380646RecruitingPhase 2
Leucogen to prevent low white blood cells from ribociclib in early breast cancer
This trial tests if Leucogen can prevent neutropenia (low white blood cells) caused by ribociclib, a targeted therapy for hormone receptor-positive, HER2-negative early breast cancer. It may help you stay on treatment without delays or dose reductions.
Hangzhou, ZhejiangAges 18 years+ - NCT05903833RecruitingPhase 2
Study pembrolizumab and lenvatinib for advanced vulvar cancer
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
AugsburgAges 18 years+ - NCT07335354Recruiting
Decision tool for breast reconstruction after mastectomy
This study is testing a decision tool to help people who are thinking about breast reconstruction surgery after a mastectomy. The tool is designed to help you and your doctor make a more informed choice.
Basking Ridge, New JerseyAges 18 years+
Hear when a new Breast Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer recurrent?
- Yes. Clin2 currently lists 632 recruiting breast cancer recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.